2021
Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance
Dong YL, Vadla GP, Lu J, Ahmad V, Klein TJ, Liu LF, Glazer PM, Xu T, Chabu CY. Cooperation between oncogenic Ras and wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance. Communications Biology 2021, 4: 374. PMID: 33742110, PMCID: PMC7979758, DOI: 10.1038/s42003-021-01898-5.Peer-Reviewed Original ResearchMeSH KeywordsA549 CellsAnimalsAnimals, Genetically ModifiedCell ProliferationCytokinesDrosophila melanogasterDrosophila ProteinsFemaleGene Expression Regulation, NeoplasticGenes, rasHumansJanus KinasesLung NeoplasmsMaleMice, NudeMice, TransgenicParacrine CommunicationRadiation ToleranceSignal TransductionSTAT Transcription FactorsTumor BurdenTumor Suppressor Protein p53Xenograft Model Antitumor AssaysConceptsTumor microenvironmentTumor radioresistanceRas clonesOncogenic Ras mutationsClinical outcomesRA tissuesCancer patientsJAK/STATRadiation therapyRobust tumorOncogenic RasTherapy outcomeTumor resistanceTumor tissueRas mutationsTumor cellsJAK/OutcomesRadioresistanceCellular responsesTissueCell-cell interactionsPatientsCytokinesRadiotherapyClinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas
Eder JP, Doroshow DB, T. K, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas. JCO Precision Oncology 2021, 5: 466-472. PMID: 34994649, PMCID: PMC9848565, DOI: 10.1200/po.20.00247.Peer-Reviewed Original ResearchConceptsPulmonary epithelioid hemangioendotheliomaStable diseaseEpithelioid hemangioendotheliomaClinical benefitClinical benefit rateOpen-label studyPrimary end pointPoly (ADP-ribose) polymerase inhibitionDefective homologous recombination (HR) repairMesenchymal sarcomaObjective responsePartial responseClinical efficacyPatient populationBenefit rateCombination trialsPatientsSolid tumorsIDH1/2-mutant tumorsIDH1/2 mutationsPARP inhibitorsEnd pointPARP inhibitionTumorsOlaparib
1999
93 The germline p53 13964 gc mutation confers resistance to radiation in familial breast cancer patients
Turner B, Lehman T, Modali R, Carbone C, Bishop L, Curran W, Glazer P, Haffty B. 93 The germline p53 13964 gc mutation confers resistance to radiation in familial breast cancer patients. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 195. DOI: 10.1016/s0360-3016(99)90111-6.Peer-Reviewed Original Research
1998
Elevated frequency of germline BRCA1/BRCA2 gene mutations in locally recurrent breast cancer patients following lumpectomy and radiation therapy: Implications for breast conserving management in affected patients
Turner B, Harrold E, Gumbs A, Matloff E, Ward B, Thomas A, Glazer P, Haffty B. Elevated frequency of germline BRCA1/BRCA2 gene mutations in locally recurrent breast cancer patients following lumpectomy and radiation therapy: Implications for breast conserving management in affected patients. International Journal Of Radiation Oncology • Biology • Physics 1998, 42: 179. DOI: 10.1016/s0360-3016(98)80210-1.Peer-Reviewed Original Research